Drugs News and Research

RSS

New report reveals potential breakthrough in pterygium treatment

A new report reveals a potential breakthrough in the treatment of a common eye ailment known as pterygium (Surfer's eye) that impacts the vision, eye health, and cosmetic appearance of countless sufferers.

1 Apr 2014

Looking ahead at health law milestones

With open enrollment for 2014 set to formally close today, analysts note that it will take years to assess whether the health law succeeds at creating stable markets for those without employer-sponsored insurance. Several look at likely victories and hurdles.

1 Apr 2014

Experimental anticancer compound appears to reverse behaviors associated with schizophrenia

Johns Hopkins researchers say that an experimental anticancer compound appears to have reversed behaviors associated with schizophrenia and restored some lost brain cell function in adolescent mice with a rodent version of the devastating mental illness.

1 Apr 2014

Rigorous blood pressure control could halve recurrent stroke risk

Ensuring that the blood pressure of stroke survivors is controlled at least three-quarters of the time may halve their risk of a recurrence, shows a secondary analysis of the VISP trial.

31 Mar 2014

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

rEVO Biologics Inc., a subsidiary of LFB SA, today announced the initiation of the Phase 3 clinical program for ATryn for the treatment of preeclampsia in pregnant women during the 24th to 28th week of pregnancy.

31 Mar 2014

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.

31 Mar 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

Artists benefit from health law, but rural residents may pay more

Self-employed Americans such as artists stand to gain under the health law, but rural residents may pay more for coverage because of the higher costs of delivering care in a sparsely populated area and the disproportionate number of older people. Other media outlets offer advice for consumers trying to make sense of the law.

31 Mar 2014

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Pacira Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL (bupivacaine liposome injectable suspension). The suite is housed at the company's Science Center Campus in San Diego, where EXPAREL is currently manufactured.

31 Mar 2014

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

31 Mar 2014

Bariatric surgery patients report better quality of life

A study by Cleveland Clinic researchers shows bariatric surgery is a highly effective and durable treatment for type 2 diabetes in obese patients, enabling nearly all surgical patients to be free of insulin and many to be free of all diabetic medications three years after surgery.

31 Mar 2014

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

31 Mar 2014

New study shows anti-anxiety drugs and sleeping pills associated with increased risk of death

Anti-anxiety drugs and sleeping pills have been linked to an increased risk of death, according to new research from the University of Warwick.

31 Mar 2014

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).

31 Mar 2014

First Edition: March 31, 2014

Today's early morning highlights from the major news organizations offer assessments of the administration's campaign to get people signed up for health care and a look at the issues going forward after today's deadline for most enrollments.

31 Mar 2014

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Clinigen Group plc ('Clinigen' or the 'Group') the specialty global pharmaceutical company today announces the acquisition of SAVENE® (dexrazoxane) from SpePharm AG, a majority owned affiliate of Norgine B.V. The Financial terms of the acquisition are not being disclosed.

From Clinigen Group 31 Mar 2014

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

EKOS Corporation, a BTG International group company, notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States.

31 Mar 2014

International scientists identify novel genetic defects that induce oesophageal cancer

A team of scientists from the Cancer Science Institute of Singapore at the National University of Singapore and National University Cancer Institute Singapore, and their collaborators from the Cedars-Sinai Medical Centre, UCLA School of Medicine, demonstrated that a number of novel genetic defects are able to induce oesophageal cancer.

31 Mar 2014

Mechanical circulatory assist device may have untapped potential in heart surgery patients, say physicians

The most frequently used mechanical circulatory assist device in the world may have untapped potential, physicians say.

31 Mar 2014

Medolac Laboratories opens new center of operations in Lake Oswego, Oregon

Many local and state dignitaries, investors, employees, donors and media, participated in the ribbon cutting ceremony on Thursday, March 27, 2014 to help christen Medolac Laboratories' flagship center of operations in Lake Oswego, Oregon.

31 Mar 2014

Drugs News and Research

New report reveals potential breakthrough in pterygium treatment

Looking ahead at health law milestones

Experimental anticancer compound appears to reverse behaviors associated with schizophrenia

Rigorous blood pressure control could halve recurrent stroke risk

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Artists benefit from health law, but rural residents may pay more

FDA approves additional manufacturing suite for Pacira’s EXPAREL

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

Bariatric surgery patients report better quality of life

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

New study shows anti-anxiety drugs and sleeping pills associated with increased risk of death

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

First Edition: March 31, 2014

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

International scientists identify novel genetic defects that induce oesophageal cancer

Mechanical circulatory assist device may have untapped potential in heart surgery patients, say physicians

Medolac Laboratories opens new center of operations in Lake Oswego, Oregon

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News